Wegovy Pill Just Changed: Why Lilly Stock Could Still Win
A new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
Find out which rewards program is best suited for your lifestyle and spending habits. Maximize your value with our expert insights!
22,671 articlesA new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
Hims & Hers announces a billion-dollar cross-border deal to expand telehealth and wellness services, signaling a bold...
Philip Morris International is steering a bold pivot toward smoke-free products, aiming to drive more than two-thirds...
Shake Shack delivered a blowout Q4, where earnings beat expectations by a wide margin and revenue surged. The company...
JPMorgan’s Jamie Dimon reveals a simple, enduring rule that shaped his ascent from a young Harvard MBA assistant to t...
Beyond shakes up its identity, dropping meat from its name to chase a broader plant protein future as plant-based sal...
I dove into Plug Power in a hopeful stretch for green energy gains, only to see a dramatic crash. This is the hard-wo...
Snowflake closes its first full year under new CEO Sridhar Ramaswamy with solid revenue gains and a bold AI strategy,...
Bond markets show renewed stress, with yields rising and liquidity thinning. Analysts say a familiar pattern is reeme...
Jay-Z, now valued at roughly $2.8 billion, argues that demonizing wealth misses the bigger fixes to inequality. The s...
Nvidia unveiled a large stake in Iren to support a 5GW global AI factory plan, sending Iren’s stock higher even as th...
Trump’s renewed push to revive the Rush Hour franchise is drawing investor attention. Analysts say licensing, streami...